Overview

Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Status:
Unknown status

Trial end date:
2016-03-01

Target enrollment:
0

Participant gender:
All

Summary

The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chen Wei Ren, MD

Treatments:

Glucagon
Glucagon-Like Peptide 1
Liraglutide

Criteria

Inclusion Criteria:

Patients were eligible if they were 18 years or older and presented within 12 h from the
onset of symptoms and signs of ST-segment elevation myocardial infarction to the
catheterization laboratory.

Exclusion Criteria:

The patients were not considered for enrolment if they presented with unconsciousness,
cardiogenic shock, hypoglycaemia, diabetic ketoacidosis, previous myocardial infarction,
stent thrombosis, known renal insufficiency, or previous coronary artery bypass operation.